Welcome to our dedicated page for Prenetics news (Ticker: PRE), a resource for investors and traders seeking the latest updates and insights on Prenetics stock.
Prenetics Global Limited (NASDAQ: PRE) generates an active stream of company news centered on its evolution as a health sciences business and the rapid growth of its IM8 premium health and longevity brand. Press releases describe Prenetics as a leading health sciences company focused on redefining the future of health and longevity through IM8, a premium core nutrition platform co-founded with David Beckham and championed by World No. 1 and four-time Grand Slam winner Aryna Sabalenka.
News updates commonly highlight IM8’s growth milestones, including disclosures that the brand reached over $100 million in annualized recurring revenue within roughly 11 months of launch and has been characterized by the company as the fastest-growing supplement brand in industry history. Articles also cover monthly revenue achievements, subscription metrics, and international expansion, reflecting IM8’s role as the centerpiece of Prenetics’ strategy.
Investors following PRE can also expect news on capital allocation and financing activities. Recent announcements include a best efforts public offering of Class A ordinary shares with accompanying warrants, a voluntary warrant exchange program designed to reduce potential dilution and simplify the capital structure, and updates on the company’s Bitcoin treasury strategy. Prenetics has communicated a shift away from new Bitcoin purchases, choosing instead to maintain existing holdings as a treasury reserve while directing new capital exclusively toward IM8.
Another recurring theme in Prenetics news is strategic portfolio optimization. Releases describe the sale of ACT Genomics, the divestiture of Europa Sports Partners, and an ongoing review of other non-core assets such as CircleDNA and the company’s stake in Insighta. These items are presented as part of a broader effort to focus on IM8 and improve operating margins.
News items may also include earnings announcements, conference participation, and insider share purchases by members of the executive leadership team, which are furnished to the SEC on Form 6-K. For readers tracking PRE, this news page provides a consolidated view of operational updates, financial developments, capital structure changes, and strategic decisions affecting Prenetics and its IM8 brand.
Prenetics (NASDAQ: PRE) reported strong Q4 and full year 2024 results, with Q4 revenue growing 93.5% to $10.5 million and full-year revenue increasing 40.9% to $30.6 million. The company maintains a solid financial position with $84.8 million in cash and short-term assets.
Key highlights include:
- Gross profit from continuing operations reached $4.6 million in Q4 2024 (up 73.1%) and $16.1 million for full-year 2024 (up 82.6%)
- Full-year gross margin improved to 52.6% from 40.6% in 2023
- IM8 Health launch showed promising results with $106 average order value and 83% subscription rate
For 2025, Prenetics projects revenue of $73-85 million, representing 350-450% year-over-year growth. The company expects to achieve profitability by Q4 2025, focusing on consumer health brands IM8, Europa, and CircleDNA.
Prenetics Global (NASDAQ: PRE) has announced a strategic partnership with Humanity Protocol to integrate its CircleDNA service for blockchain-based identity verification. The collaboration aims to provide secure Proof of Personhood credentials using DNA testing and zero-knowledge proof technology.
The company has established a Crypto Strategic Reserve with initial investments of $1.5M distributed across $H tokens ($1M), Bitcoin ($250K), and Solana ($250K). These investments will be reviewed quarterly. Prenetics reported $84.87M in cash and short-term assets as of December 31, 2024.
Additionally, through its joint venture Insighta, Prenetics is advancing in decentralized science (DeSci) with AI-driven early cancer detection, supported by a $30M investment from Tencent. The company's consumer health brand, IM8, is also contributing to DeSci initiatives by applying scientific advancements to daily health and longevity solutions.
IM8, a premium supplements brand co-founded by David Beckham, celebrated its U.S. launch with events in New York City on January 14, 2025. The launch featured two main segments: an Inside Out Wellness session with Deepak Chopra and Beckham, and an evening event with the Scientific Advisory Board.
The wellness session included tasting of IM8's Daily Ultimate Essentials product and a meditation session. The evening featured panel discussions with medical experts and a conversation between Beckham and Fast Company's Jeff Beer about his involvement with IM8.
The company reported increased customer interest following Beckham's TODAY Show appearance and influencer coverage. The brand's Daily Ultimate Essentials product recently received NSF Certified for Sport® certification, validating its safety and quality standards.
Prenetics' IM8, a premium supplements brand co-founded by David Beckham, has announced that its flagship product, Daily Ultimate Essentials, has received NSF Certified for Sport® certification. This prestigious certification validates the product's safety, quality, and transparency through rigorous testing of over 280 banned substances, heavy metals, pesticides, and contaminants.
The certification ensures compliance with major athletic organizations including WADA, MLB, NFL, NBA, and PGA. Every production batch undergoes testing to maintain consistency and quality. The product is designed as an all-in-one formula replacing 16 supplements with 92 nutrient-rich ingredients.
IM8 Daily Ultimate Essentials is priced at US$79 for subscription ($99 one-time) and ships to 31 countries. The company is offering a welcome launch package including a signature red cup and five travel sachets valued at US$46.
Prenetics' IM8 has announced a collaboration with Mayo Clinic to develop a new line of premium supplements, focusing on nutrition, cellular rejuvenation, protein, collagen, and overall wellness. The partnership, announced after IM8's official launch on November 18th on IM8health.com, combines IM8's innovation with Mayo Clinic's medical expertise to create evidence-based, clinically researched supplements.
The collaboration includes contributions from Dr. Dawn Mussallem, a Mayo Clinic integrative oncologist who serves on IM8's Scientific Advisory Board. Mayo Clinic maintains a financial interest in the referenced technology and will direct any revenue toward its not-for-profit mission in patient care, education, and research.
Prenetics' IM8 has launched a groundbreaking space experiment aboard the International Space Station (ISS) in collaboration with the University of Oxford, supported by Space Applications Services. The mission, launched via SpaceX CRS-31 on November 4th, aims to study accelerated aging and longevity using microgravity's unique environment.
The experiment focuses on autophagy, the cellular process of removing and recycling damaged components, using 3D organoids in a specially designed science cube. The research leverages microgravity's ability to accelerate aging processes, potentially leading to insights for improving human healthspan and astronaut health.
Coinciding with this research, IM8 officially launched its premium supplements brand on November 18th on IM8health.com, offering two products: Daily Ultimate Essentials and Daily Ultimate Longevity, now shipping to 31 countries.
Prenetics Global (NASDAQ: PRE) has announced its participation in two upcoming investor conferences in December 2024. The company will attend the iAccess Alpha Virtual Best Ideas Winter Conference on December 10-11, where CEO Danny Yeung will present on December 10 at 10:00am ET, followed by one-on-one meetings with CFO Stephen Lo and Prenetics Americas President David Vanderveen on December 11.
Additionally, David Vanderveen will represent the company at the 13th Annual ROTH Deer Valley Event in Park City, UT from December 11-13, conducting one-on-one investor meetings throughout the conference.
Prenetics Global reported strong Q3 2024 results with revenue growing 59.4% year-over-year to $7.8 million and 30.9% sequentially. Gross profit increased 138.6% to $3.9 million, with gross margin improving to 50.8%. The company launched IM8Health.com, a premium supplements brand, shipping to 31 countries. Notable developments include Tencent's $30 million strategic investment in Insighta, validating its $200 million valuation, and the acquisition of Europa Sports Partners establishing U.S. headquarters in Charlotte. The company maintains a strong financial position with $69.1 million in cash and short-term assets, remaining debt-free, and reiterates its FY 2024 revenue target to exceed $33 million.
Prenetics (NASDAQ: PRE) and David Beckham have officially launched IM8, a health and wellness brand entering the $187 billion global consumer health market. The launch features two premium products: Daily Ultimate Essentials, an all-in-one powder with 92 nutrient-rich ingredients replacing 16 separate supplements, and Daily Ultimate Longevity, a daily capsule for cellular rejuvenation. A clinical trial showed that 93% of participants experienced increased energy levels within 30 days using Daily Ultimate Essentials. The products are available in 31 countries through IM8health.com, with subscription pricing at $79 for Essentials and $75 for Longevity. The launch follows Prenetics' acquisition of Europa, a major U.S. sports nutrition distributor.
Prenetics (NASDAQ: PRE) and David Beckham have officially launched IM8, a health and wellness brand entering the $187 billion global consumer health market. The launch introduces two premium products: Daily Ultimate Essentials, an all-in-one powder containing 92 nutrient-rich ingredients replacing 16 separate supplements, and Daily Ultimate Longevity, a daily capsule for cellular rejuvenation. Clinical trials showed significant benefits with 93% of participants experiencing increased energy levels. The products are available in 31 countries through IM8health.com, with subscription pricing at $79 for Essentials and $75 for Longevity. The launch follows Prenetics' acquisition of Europa, a major U.S. sports nutrition distributor.
FAQ
What is the current stock price of Prenetics (PRE)?
What is the market cap of Prenetics (PRE)?
